Article Text
Abstract
Introduction Catecholamines such as adrenaline (epinephrine) and noradrenaline (norepinephrine) are hormones that play a critical role in the body’s ‘fight or flight’ response, which is the physiological response to stress. Considerable evidence has accumulated in the last decade to support the notion that chronic stress is closely related to the growth, metastasis, and angiogenesis of ovarian cancer. The purpose of this study was to identify factors that increase the progression of ovarian cancer and to determine the possibility of inhibiting ovarian cancer progression using novel therapeutics.
Methods In this study, we analyzed the conditioned media in SKOV3 ovarian cancer cell line treated with catecholamine to identify secreted proteins responding to chronic stress.
Results We observed that epinephrine and norepinephrine enhanced the secretion and mRNA expression of CXC-chemokines (CXCL1, 2, 3, and 8). Neutralizing antibody to CXCL8 and CXCL8 receptor (CXCR2) inhibitors significantly reduced catecholamine-mediated invasion of SKOV3 cells. Finally, we found that the concentration of CXCL1 and CXCL8 in the plasma of ovarian cancer patients increased with stage progression.
Conclusion/Implications Therefore, not only can CXCL1 and CXCL8 be used as diagnostic markers for ovarian cancer, but their inhibition also holds promise as a potential therapeutic option for suppressing ovarian cancer progression. Taken together, these findings suggest that stress-related catecholamines may influence ovarian cancer progression through the secretion of CXC-chemokines.